מדינה: סינגפור
שפה: אנגלית
מקור: HSA (Health Sciences Authority)
IMMUNOGLOBULIN (HUMAN)
GRIFOLS ASIA PACIFIC PTE. LTD.
J06BA02
50 mg/ml
INJECTION
IMMUNOGLOBULIN (HUMAN) 50 mg/ml
INTRAVENOUS
Prescription Only
BIOTEST AG
ACTIVE
1999-10-29
185081 003 INSTRUCTIONS FOR USE / PATIENT INFORMATION LEAFLET Active ingredient: Human normal immunoglobulin for intravenous administration COMPOSITION 1 ml solution contains: – ACTIVE INGREDIENT: Human plasma protein 50 mg of which immunoglobulin is at least 95 % Immunoglobulin M (IgM) 6 mg Immunoglobulin A (IgA) 6 mg Immunoglobulin G (IgG) 38 mg – EXCIPIENTS: Glucose monohydrate (27.5 mg), sodium chloride (78 µmol), water for injections ad 1 ml The distribution of IgG subclasses is approx. 63 % IgG1, 26 % IgG2, 4 % IgG3 and 7 % IgG4 PRESENTATIONS AND CONTENTS OF CONTAINER Solution for intravenous infusion. Ampoule with 10 ml (0.5 g) Vial with 50 ml (2.5 g), infusion set on request Vial with 100 ml (5.0 g), infusion set on request PHARMACOTHERAPEUTIC GROUP Human immunoglobulin NAME AND ADDRESS OF AUTHORISATION HOLDER AND MANUFACTURER Biotest Pharma GmbH Landsteinerstrasse 5 63303 Dreieich Germany INDICATIONS Adjuvant therapy of severe bacterial infections additional to antibiotic therapy. Product is only intended for use in high risk patients with proven bacterial sepsis and who are unlikely to have underlying IgA deficiency. Immunoglobulin substitution in immunocompromized patients. CONTRAINDICATIONS Hypersensitivity to any of the components of the product. Hypersensitivity to homologous immunoglobulins, especially in very rare cases of IgA deficiency, when the patient has antibodies against IgA. 185.081.003.indd 1 28.02.2011 11:45:07 Uhr PREGNANCY AND LACTATION The safety of this medicinal product for use in human pregnancy has not been estab- lished in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding mothers. Clinical experience with immunoglobu- lins suggests that no harmful effects on the course of pregnancy, or on the foetus and קרא את המסמך השלם
1 Package leaflet: Information for the user PENTAGLOBIN® Active substance: Human normal immunoglobulin for intravenous administration COMPOSITION One ml solution contains: - Active substance: Human plasma protein 50 mg of which immunoglobulin is at least 95% Immunoglobulin M (IgM) 6 mg Immunoglobulin A (IgA) 6 mg Immunoglobulin G (IgG) 38 mg - excipients: Glucose monohydrate (27.5 mg) corresponding to 25mg glucose, sodium chloride (78 µmol), water for injections ad 1 ml The distribution of IgG subclasses is approx. 63% IgG1, 26% IgG2, 4% IgG3 and 7% IgG4 PHARMACEUTICAL FORM AND CONTENTS OF CONTAINER Solution for intravenous infusion. Pack size of 1 vial with 10 ml (0.5 g), 50 ml (2.5 g) or 100 ml (5.0 g) solution. PHARMACOTHERAPEUTIC GROUP Immunoglobulins, normal human, for intravascular administration NAME AND ADDRESS OF AUTHORISATION HOLDER AND MANUFACTURER Biotest Pharma GmbH Landsteinerstrasse 5 63303 Dreieich Germany INDICATIONS Adjuvant therapy of severe bacterial infections additional to antibiotic therapy. Product is only intended for use in high risk patients with proven bacterial sepsis and who are unlikely to have underlying IgA deficiency. Immunoglobulin substitution in immunocompromized patients. CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed above. Hypersensitivity to human immunoglobulins, especially in patients with antibodies against IgA. PREGNANCY AND LACTATION The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding mothers. IVIg products have been shown to cross the placenta, increasingly during the third trimester. Pentaglobin also contains IgM which does not cross the placenta. Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are to be expected. IgG are excreted into the milk and may contribute to the transfer of p קרא את המסמך השלם